Cargando…
An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
INTRODUCTION: Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of Td...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835515/ https://www.ncbi.nlm.nih.gov/pubmed/26860921 http://dx.doi.org/10.1007/s40264-016-0393-1 |
_version_ | 1782427617477001216 |
---|---|
author | Lorberbaum, Tal Sampson, Kevin J. Woosley, Raymond L. Kass, Robert S. Tatonetti, Nicholas P. |
author_facet | Lorberbaum, Tal Sampson, Kevin J. Woosley, Raymond L. Kass, Robert S. Tatonetti, Nicholas P. |
author_sort | Lorberbaum, Tal |
collection | PubMed |
description | INTRODUCTION: Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of TdP, but drug–drug interactions contributing to LQTS (QT-DDIs) remain poorly characterized. Traditional methods for mining observational healthcare data are poorly equipped to detect QT-DDI signals due to low reporting numbers and lack of direct evidence for LQTS. OBJECTIVE: We hypothesized that LQTS could be identified latently using an adverse event (AE) fingerprint of more commonly reported AEs. We aimed to generate an integrated data science pipeline that addresses current limitations by identifying latent signals for QT-DDIs in the US FDA’s Adverse Event Reporting System (FAERS) and retrospectively validating these predictions using electrocardiogram data in electronic health records (EHRs). METHODS: We trained a model to identify an AE fingerprint for risk of TdP for single drugs and applied this model to drug pair data to predict novel DDIs. In the EHR at Columbia University Medical Center, we compared the QTc intervals of patients prescribed the flagged drug pairs with patients prescribed either drug individually. RESULTS: We created an AE fingerprint consisting of 13 latently detected side effects. This model significantly outperformed a direct evidence control model in the detection of established interactions (p = 1.62E−3) and significantly enriched for validated QT-DDIs in the EHR (p = 0.01). Of 889 pairs flagged in FAERS, eight novel QT-DDIs were significantly associated with prolonged QTc intervals in the EHR and were not due to co-prescribed medications. CONCLUSIONS: Latent signal detection in FAERS validated using the EHR presents an automated and data-driven approach for systematically identifying novel QT-DDIs. The high-confidence hypotheses flagged using this method warrant further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0393-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4835515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-48355152016-05-04 An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval Lorberbaum, Tal Sampson, Kevin J. Woosley, Raymond L. Kass, Robert S. Tatonetti, Nicholas P. Drug Saf Original Research Article INTRODUCTION: Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of TdP, but drug–drug interactions contributing to LQTS (QT-DDIs) remain poorly characterized. Traditional methods for mining observational healthcare data are poorly equipped to detect QT-DDI signals due to low reporting numbers and lack of direct evidence for LQTS. OBJECTIVE: We hypothesized that LQTS could be identified latently using an adverse event (AE) fingerprint of more commonly reported AEs. We aimed to generate an integrated data science pipeline that addresses current limitations by identifying latent signals for QT-DDIs in the US FDA’s Adverse Event Reporting System (FAERS) and retrospectively validating these predictions using electrocardiogram data in electronic health records (EHRs). METHODS: We trained a model to identify an AE fingerprint for risk of TdP for single drugs and applied this model to drug pair data to predict novel DDIs. In the EHR at Columbia University Medical Center, we compared the QTc intervals of patients prescribed the flagged drug pairs with patients prescribed either drug individually. RESULTS: We created an AE fingerprint consisting of 13 latently detected side effects. This model significantly outperformed a direct evidence control model in the detection of established interactions (p = 1.62E−3) and significantly enriched for validated QT-DDIs in the EHR (p = 0.01). Of 889 pairs flagged in FAERS, eight novel QT-DDIs were significantly associated with prolonged QTc intervals in the EHR and were not due to co-prescribed medications. CONCLUSIONS: Latent signal detection in FAERS validated using the EHR presents an automated and data-driven approach for systematically identifying novel QT-DDIs. The high-confidence hypotheses flagged using this method warrant further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0393-1) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-02-10 2016 /pmc/articles/PMC4835515/ /pubmed/26860921 http://dx.doi.org/10.1007/s40264-016-0393-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Lorberbaum, Tal Sampson, Kevin J. Woosley, Raymond L. Kass, Robert S. Tatonetti, Nicholas P. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval |
title | An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval |
title_full | An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval |
title_fullStr | An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval |
title_full_unstemmed | An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval |
title_short | An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval |
title_sort | integrative data science pipeline to identify novel drug interactions that prolong the qt interval |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835515/ https://www.ncbi.nlm.nih.gov/pubmed/26860921 http://dx.doi.org/10.1007/s40264-016-0393-1 |
work_keys_str_mv | AT lorberbaumtal anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT sampsonkevinj anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT woosleyraymondl anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT kassroberts anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT tatonettinicholasp anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT lorberbaumtal integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT sampsonkevinj integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT woosleyraymondl integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT kassroberts integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval AT tatonettinicholasp integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval |